Discovery platform for inhibitors of IgH gene enhancer activity

7Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Immunoglobulin heavy chain (IgH) translocations are common and early oncogenic events in B cell and plasma cell malignancies including B cell non-Hodgkin’s lymphoma (NHL) and multiple myeloma (MM). IgH translocations bring oncogenes into close proximity with potent enhancer elements within the IgH locus, leading to oncogene up-regulation. As IgH enhancer activity is tightly controlled by B cell lineage-specific signaling and transcriptional networks, we hypothesized that IgH enhancers are potentially druggable targets/elements. To test this, we developed a molecular imaging-based high-throughput screening platform for discovering inhibitors of IgH enhancer-driven transcriptional activity. As proof of concept, we identified a low micromolar potency molecule (compound 30666) that inhibited immunoglobulin production by MM cells and blocked expression of an array of IgH translocation-induced oncogenes (CCND1, FGFR3/MMSET, and MYC) in MM and NHL cell lines. Prolonged exposure to 30666 significantly reduced the viability of IgH translocation-positive NHL and MM cells, but was less effective against cells lacking IgH translocations. Compound 30666 exhibited suitable pharmacological properties, including metabolic stability in liver microsomes and oral bioavailability in mice, and demonstrated preclinical anti-MM activity in a plasmacytoma mouse model. Our work suggests that IgH enhancers are attractive and potentially druggable targets for IgH translocation driven malignancies.

References Powered by Scopus

Initial sequencing and comparative analysis of the mouse genome

5733Citations
N/AReaders
Get full text

The accessible chromatin landscape of the human genome

2009Citations
N/AReaders
Get full text

Architecture of the human regulatory network derived from ENCODE data

1156Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Genome instability in multiple myeloma: Facts and factors

24Citations
N/AReaders
Get full text

Enhancing b-cell malignancies—on repurposing enhancer activity towards cancer

7Citations
N/AReaders
Get full text

Exploring the genetic and molecular basis of differences in multiple myeloma of individuals of African and European descent

4Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Dolloff, N. G. (2019). Discovery platform for inhibitors of IgH gene enhancer activity. Cancer Biology and Therapy, 20(4), 571–581. https://doi.org/10.1080/15384047.2018.1538615

Readers over time

‘19‘20‘21‘22‘23‘2402468

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 5

56%

Researcher 4

44%

Readers' Discipline

Tooltip

Medicine and Dentistry 5

42%

Agricultural and Biological Sciences 3

25%

Biochemistry, Genetics and Molecular Bi... 3

25%

Pharmacology, Toxicology and Pharmaceut... 1

8%

Save time finding and organizing research with Mendeley

Sign up for free
0